Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene test could Fine-Tune chemo doses for rare cancer patients

NCT ID NCT06406465

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 29 times

Summary

This study aims to see if adjusting the dose of the drug belinostat based on a person's genes can make treatment safer and more effective for high-grade neuroendocrine carcinomas. About 60 adults with this rare cancer will receive belinostat along with two other chemotherapy drugs in 21-day cycles. Researchers will monitor how the body processes the drug and check tumor response using scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.